PCOS and Cardiovascular Risk: What Your Hormonal Diagnosis Means for Your Heart

When a gynaecologist confirms PCOS, the conversation almost always centres on irregular periods, weight, or fertility. The heart rarely comes up. A 2023 meta-analysis published in the European Heart Journal, covering data from over 900,000 women, found that those with PCOS face a 30 to 40% higher risk of coronary artery disease and a significantly elevated risk of stroke compared to women without the condition. That number does not appear on most discharge summaries.
The reason the cardiac risk is underplayed is partly structural. PCOS sits between specialties. Gynaecologists manage the reproductive symptoms. Endocrinologists manage the metabolic ones. Cardiologists rarely see a 25-year-old woman with irregular cycles. The result is that the cardiovascular thread gets dropped between departments, and women spend years managing symptoms without understanding the longer arc.
Approximately 70 to 80% of women with PCOS have some degree of insulin resistance, even those who are not overweight. When cells stop responding efficiently to insulin, the pancreas compensates by producing more. Elevated insulin then stimulates the ovaries to produce excess androgen. The androgen excess drives the visible PCOS symptoms, acne, hirsutism, anovulation, but the metabolic damage is happening at a different level entirely.
Chronically high insulin promotes visceral fat accumulation, raises triglycerides, lowers HDL cholesterol, and drives up blood pressure over time. Each of these is an independent cardiovascular risk factor. Together, they constitute metabolic syndrome, which the Indian Council of Medical Research has flagged as disproportionately prevalent among Indian women with PCOS, partly because South Asian women tend to develop insulin resistance at lower BMI thresholds than Western populations. A woman with PCOS who appears metabolically normal by standard BMI criteria may still carry significant visceral adiposity and insulin dysfunction.

PCOS is now understood to be a state of low-grade chronic inflammation. C-reactive protein, a marker of systemic inflammation, is consistently elevated in women with PCOS compared to matched controls. This matters for the heart because inflammation accelerates atherosclerosis, the buildup of plaque in arterial walls that precedes most heart attacks and strokes.
The inflammatory state in PCOS appears to be independent of obesity. Lean women with PCOS show elevated inflammatory markers too, which means body weight is not a reliable proxy for cardiac risk in this population. A 2020 study in the Journal of Clinical Endocrinology and Metabolism confirmed that oxidative stress and inflammatory cytokines remain elevated in normal-weight PCOS patients, challenging the assumption that weight loss alone resolves the underlying cardiovascular risk.

Three interventions have the clearest evidence for reducing cardiovascular risk specifically in women with PCOS, and none of them is a PCOS-specific drug.
Resistance training, done at least three times a week, improves insulin sensitivity more effectively than equivalent volumes of cardio in women with PCOS, according to a 2019 trial in Fertility and Sterility. The mechanism is skeletal muscle acting as a glucose sink, more muscle mass means more sites for glucose uptake independent of insulin signalling.

Dietary patterns that reduce glycaemic load, reducing refined carbohydrates like maida and white rice, increasing fibre from dal, vegetables, and whole grains, lower fasting insulin and reduce androgen production downstream. This does not require a caloric deficit to work. The hormonal benefit appears even at stable weight when the glycaemic load drops.
Metformin, typically prescribed for type 2 diabetes, is used off-label in PCOS and has a reasonable evidence base for reducing insulin resistance and lowering androgen levels. For women with confirmed insulin resistance, it also reduces the progression toward type 2 diabetes, which is itself a major cardiac risk amplifier. The decision to use it belongs to an endocrinologist, not a gynaecologist alone, which is an argument for seeking a dual consult rather than managing PCOS within a single specialty.
Most women with PCOS are not routinely screened for the cardiovascular markers that would catch early deterioration. A fasting lipid panel, fasting insulin, HbA1c, and blood pressure check once a year gives a far more complete picture of where the risk actually sits than a pelvic ultrasound and a hormone panel alone.
The window between a PCOS diagnosis in the twenties and a first cardiac event, which, for women with PCOS, tends to arrive a decade earlier than in the general female population, is long enough to change the outcome substantially. The metabolic damage is slow and cumulative. So is the reversal.
A PCOS diagnosis is not a cardiovascular sentence. The hormonal dysfunction and the insulin resistance that drive cardiac risk are both modifiable. But they are only modifiable if they are being tracked, and that requires a woman to understand that her gynaecological condition has a cardiac dimension her doctors may not have named.